Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D03345 (
beta-Galactosidase
)
434
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It has been reported that genomic DNA methylation decreases gradually during cell culture and an organism's aging. However, less is known about the methylation changes of age-related specific genes in aging.
p21
(Waf1/Cip1) and p16(INK4a) are cyclin-dependent kinase (Cdk) inhibitors that are critical for the replicative senescence of normal cells. In this study, we show that
p21
(Waf1/Cip1) and p16(INK4a) have different methylation patterns during the aging process of normal human 2BS and WI-38 fibroblasts.
p21
(Waf1/Cip1) promoter is gradually methylated up into middle-aged fibroblasts but not with senescent fibroblasts, whereas p16(INK4a) is always unmethylated in the aging process. Correspondently, the protein levels of DNA methyltransferase 1 (DNMT1) and DNMT3a increase from young to middle-aged fibroblasts but decrease in the senescent fibroblasts, while DNMT3b decreases stably from young to senescent fibroblasts.
p21
(Waf1/Cip1) promoter methylation directly represses its expression and blocks the radiation-induced DNA damage-signaling pathway by p53 in middle-aged fibroblasts. More importantly, demethylation by 5-aza-CdR or DNMT1 RNA interference (RNAi) resulted in an increased
p21
(Waf1/Cip1) level and premature senescence of middle-aged fibroblasts demonstrated by cell growth arrest and high
beta-Galactosidase
expression. Our results suggest that
p21
(Waf1/Cip1) but not p16(INK4a) is involved in the DNA methylation mediated aging process.
p21
(Waf1/Cip1) promoter methylation may be a critical biological barrier to postpone the aging process.
...
PMID:p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation. 1651 63
We tested a hypothesis that activation of growth-promoting pathways is required for cellular senescence. In the presence of serum, induction of
p21
caused senescence, characterized by
beta-Galactosidase
staining, cell hypertrophy, increased levels of cyclin D1 and active TOR (target of rapamycin, also known as mTOR). Serum starvation and rapamycin inhibited TOR and prevented the expression of some senescent markers, despite high levels of
p21
and cell cycle arrest. In the presence of serum,
p21
-arrested cells irreversibly lost proliferative potential. In contrast, when cells were arrested by
p21
in the absence of serum, they retained the capacity to resume proliferation upon termination of
p21
induction. In normal human cells such as WI38 fibroblasts and retinal pigment epithelial (RPE) cells, serum starvation caused quiescence, which was associated with low levels of cyclin D1, inactive TOR and slim-cell morphology. In contrast, cellular senescence with high levels of TOR activity was induced by doxorubicin (DOX), a DNA damaging agent, in the presence of serum. Inhibition of TOR partially prevented senescent phenotype caused by DOX. Thus growth stimulation coupled with cell cycle arrest leads to senescence, whereas quiescence (a condition with inactive TOR) prevents senescence.
...
PMID:Growth stimulation leads to cellular senescence when the cell cycle is blocked. 1894 31